Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
|Articles|October 2, 2013
- Pharmaceutical Technology-10-02-2013
- Volume 37
- Issue 10
RheocalcT Software Tests Parameters and Data Collection
Author(s)Melanie Sena
RheocalcT Software Tests Parameters and Data Collection
RheocalcT Software allows the operator to automate viscosity testing from a PC when using the DV3T Touch Screen Rheometer and the DV2T Touch Screen Viscometer. The user interface for RheocalcT has a range of choices for test method creation and data gathering/analysis. Loop functions allow performance of repetitive tasks on test samples that require viscosity measurement at multiple rotational speeds, different temperature set points, and discreet time intervals. Viscosity data averaging is possible for individual tasks within a test step or over multiple steps in the total test program. Advanced data analysis to assess yield stress and pseudo plastic index can be performed with a choice of math models: Bingham, Casson, NCA/CMA Casson, Power Law, IPC Paste, and Herschel-Bulkley.
Articles in this issue
about 13 years ago
Q&A with Amie Gehris, Dow Water and Process Solutionsabout 13 years ago
Unraveling the Mystery of Ireland's Pharm-Attractionsabout 13 years ago
Report from: Middle East and North Africaabout 13 years ago
Maintaining and Verifying the Cold Chainabout 13 years ago
Ensuring Compliance with Drug Accountability Requirementsabout 13 years ago
The Expense of Vision in Outsourcingabout 13 years ago
LCMS-8050 Mass Spectrometer Increases Quality Analysisabout 13 years ago
Tracking Quality in Drug Manufacturingabout 13 years ago
USP Seeks Input on Standards for Plastic Packaging SystemsRelated to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.